Restoration of branched chain amino acid catabolism improves kidney function in preclinical cardiovascular-kidney-metabolic syndrome models
Kidney International · 2025-08 · 108 (2) · 310-316
DOI: 10.1016/j.kint.2025.04.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney International, 2025-08. Verfasst von Eliza Bollinger und 30 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, Pfizer Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA. Electronic address: eliza.bollinger@pfizer.com. Hauptthemen laut MEDLINE: Amino Acids, Branched-Chain, Kidney, Metabolic Syndrome, Cardio-Renal Syndrome. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Joslin Diabetes Center, Pfizer, Migrant Education Program.
Abstract (Originalsprache)
INTRODUCTION: Patients with metabolic syndrome and heart failure (HF) often have accompanying kidney dysfunction, which was recently defined as cardiovascular-kidney-metabolic (CKM) syndrome. Prior metabolomics profiling of metabolic syndrome patients identified a plasma branched chain amino acid (BCAA) signature, and BCAAs themselves are elevated in the myocardium of patients with HF, potentially due to a defect in BCAA catabolic breakdown. The rate limiting step of BCAA catabolism is the decarboxylation by the enzyme branched chain ketoacid dehydrogenase (BCKDH), which is negatively regulated by BCKDH kinase (BCKDK or BDK), and BDK inhibitors improve metabolism and heart failure preclinically. METHODS: Here, using two pre-clinical CKM models, the hyperphagic ZSF1 obese rat and the uninephrectomized SDT fatty rat with high salt drinking water, we applied unbiased proteomic, transcriptomic and metabolomic profiling to assess overall kidney gene expression and mitochondrial function. RESULTS: We show that BCAA catabolic impairment is associated with and may be causal to CKM and demonstrated impairment in BCAA catabolism within ZSF1 obese rat kidneys. In both CKM animal models, treatment with the BDK inhibitor BT2 improved urine protein content, kidney hypertrophy, and kidney pathology. Furthermore, coadministration of BT2 and the sodium-glucose cotransporter-2 inhibitor empagliflozin demonstrated additive effects to improve kidney parameters, kidney gene expression signatures, and kidney mitochondrial density and function. CONCLUSIONS: Our study suggests that in addition to its previously reported beneficial effects on metabolism and cardiac function, BDK inhibition may also improve kidney health and therefore could represent a new therapeutic avenue for CKM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine, Pfizer Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA. Electronic address: eliza.bollinger@pfizer.com.
- Internal Medicine, Pfizer Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA.
- Preclinical and Translational Sciences, Pfizer Worldwide Research, Development and Medical, Cambridge Massachusetts, USA.
- Inflammation and Immunology, Pfizer Worldwide Research, Development and Medical, Cambridge Massachusetts, USA.
- Data Sciences and Analytics, Pfizer Worldwide Research, Development and Medical, Cambridge Massachusetts, USA.
- Internal Medicine, Pfizer Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA. Electronic address: rjroth2@gmail.com.
Förderung
- Joslin Diabetes Center
- Pfizer
- Migrant Education Program
Zitieren
APA
Bollinger, E., Williams, G., Piper, M. E., Steen, K., Neale, K. T., Chen, X., Marshall, M., Jagarlapudi, S., Jami-Alahmadi, Y., Jean-Beltran, P. M., Song, L., Chiou, J., Geoly, F., Vargas, S. R., Zhang, Y., Kuang, E., Callahan, D., Stansfield, J. C., Russo, M., …, & Roth Flach, R. J. (2025). Restoration of branched chain amino acid catabolism improves kidney function in preclinical cardiovascular-kidney-metabolic syndrome models. Kidney International, 108(2), 310-316. https://doi.org/10.1016/j.kint.2025.04.025
Vancouver
Bollinger E, Williams G, Piper ME, Steen K, Neale KT, Chen X, et al. Restoration of branched chain amino acid catabolism improves kidney function in preclinical cardiovascular-kidney-metabolic syndrome models. Kidney International. 2025;108(2):310-316. doi:10.1016/j.kint.2025.04.025
BibTeX
@article{Bollinger2025,
author = {Bollinger, Eliza and Williams, George and Piper, Mary E and Steen, Kimberly and Neale, Kelly Tam and Chen, Xian and Marshall, Mackenzie and Jagarlapudi, Srinath and Jami-Alahmadi, Yasaman and Jean-Beltran, Pierre M and Song, LouJin and Chiou, Joshua and Geoly, Frank and Vargas, Sarah R and Zhang, Ying and Kuang, Elaine and Callahan, Daniel and Stansfield, John C and Russo, Max and Griffin, John and Sun, Zhongyuan and Miller, Melissa R and Hyde, Craig L and Clasquin, Michelle F and Hales, Katherine and Daurio, Natalie A and Crane, Justin D and Hirenallur-Shanthappa, Dinesh and Groarke, John and Zhang, Bei B and Roth Flach, Rachel J},
title = {Restoration of branched chain amino acid catabolism improves kidney function in preclinical cardiovascular-kidney-metabolic syndrome models},
journal = {Kidney International},
year = {2025},
volume = {108},
number = {2},
pages = {310--316},
doi = {10.1016/j.kint.2025.04.025}
}
EUVIMED